<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Complications of mannitol therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Complications of mannitol therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Complications of mannitol therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a>, given as a hypertonic solution, is primarily used in the treatment of cerebral edema and glaucoma. Although generally well tolerated, a variety of fluid, electrolyte, and kidney complications can occur if the patient is not carefully monitored. (See  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'Mannitol'</a> and  <a class="medical medical_review" href="/d/html/6903.html" rel="external">"Angle-closure glaucoma", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Volume depletion and hypernatremia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> is freely filtered by the glomerulus and does not undergo tubular reabsorption. Thus, it acts as an osmotic diuretic, increasing urinary losses of both sodium and electrolyte-free water. Lack of replacement of the fluid losses can lead to both volume depletion and hypernatremia that can be severe [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis</span><span class="headingEndMark"> — </span>If very high doses of hypertonic <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> are infused, or if the drug is given to patients with preexisting kidney failure, mannitol is retained in the circulation [<a href="#rid2">2-4</a>]. The ensuing rise in plasma osmolality, similar to that produced by hyperglycemia, results in the osmotic movement of water and potassium out of cells leading to extracellular fluid volume expansion (and possibly pulmonary edema), hyponatremia, metabolic acidosis (by dilution), and hyperkalemia [<a href="#rid5">5,6</a>]. Water losses from brain cells cause neurologic symptoms. Volume expansion and dilutional hyponatremia, without neurologic symptoms, can also be induced when isotonic mannitol is used as a flushing solution during transurethral resection of the prostate or bladder. (See  <a class="medical medical_review" href="/d/html/2363.html" rel="external">"Hyponatremia following transurethral resection, hysteroscopy, or other procedures involving electrolyte-free irrigation"</a>.)</p><p>The rise in the plasma potassium concentration following hypertonic <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> is due to the movement of potassium out of the cells into the extracellular fluid via two mechanisms [<a href="#rid6">6</a>]: (1) the rise in cell potassium concentration induced by water loss favors passive potassium exit through potassium channels in the cell membrane; and (2) the frictional forces between solvent (water) and solute can result in potassium being carried out through the water pores in the cell membrane (a process that is called solvent drag). A similar process can occur with acute hypernatremia [<a href="#rid7">7</a>] and also largely accounts for the hyperkalemia that is commonly seen with marked hyperglycemia in uncontrolled diabetes mellitus [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis"</a>.)</p><p>If kidney function is normal, the transient shift of potassium out of cells due to <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> seldom leads to hyperkalemia. A study of 45 patients treated for several days with mannitol (average dose, 28 g every six hours) for neurosurgical conditions found only one patient (2.4 percent) with a serum potassium above 5.5 mEq/L on the first day, and no patients with hyperkalemia on subsequent days [<a href="#rid10">10</a>]. By contrast, 22 percent of patients developed hypokalemia (serum potassium &lt;3.5 mEq/L) on the first day, and this proportion increased to 52 percent by the third day. Hypokalemia is likely caused at least in part by increased flow rates in the aldosterone-responsive distal nephron (caused by osmotic diuresis), which leads to increased obligatory potassium losses.</p><p class="headingAnchor" id="H5"><span class="h2">Plasma osmolal gap</span><span class="headingEndMark"> — </span>The concentration of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> in the plasma can be estimated from an increase in the plasma osmolal gap, which is the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality [<a href="#rid11">11,12</a>]. The latter assumes that sodium salts (chloride and bicarbonate), glucose, and urea nitrogen are the primary solutes in the plasma and can be estimated from the following formula:</p><div class="formulaContainer"><div class="formula"><p>  Calculated Posm  =  2  x  Plasma Na (mEq/L) + [Glucose]/18 + Blood urea nitrogen/2.8</p></div></div><p>The plasma sodium is multiplied by two to account for accompanying anions (chloride and bicarbonate) and dividing by 18 and 2.8 for the glucose and blood urea nitrogen convert units of mg/dL into mmol/L [<a href="#rid11">11</a>]. The corrections for glucose and blood urea nitrogen are not necessary in countries that report the concentrations in mmol/L.</p><p>A number of other formulas have been used to estimate the plasma osmolal gap. There appears to be no significant difference between the accuracy of the different formulas and their correlation with plasma <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> concentrations [<a href="#rid13">13</a>]. To avoid acute kidney injury (AKI), the plasma osmolal gap should not be allowed to exceed 55 mosmol/kg when mannitol is used in the treatment of cerebral edema. In animal models, a plasma mannitol concentration above 1000 mg/dl (ie, above approximately 55 mosmol/kg) produces renal vasoconstriction, whereas lower concentrations are generally associated with increased renal blood flow and decreased renal vascular resistance [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/2334.html" rel="external">"Serum osmolal gap"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>Patients with marked <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> accumulation (plasma osmolal gap greater than 60 to 75 mosmol/kg, which reflects a plasma mannitol concentration above 1080 mg/dL) may develop reversible AKI [<a href="#rid3">3,14-16</a>]. This complication is essentially limited to patients treated with more than 200 to 300 g of mannitol per day [<a href="#rid17">17,18</a>]. The required dose varies with baseline kidney function. AKI in patients with normal baseline kidney function is usually seen when the total mannitol dose exceeds 1100 g. By contrast, much smaller doses (&gt;300 g) can precipitate AKI in patients with preexisting kidney disease.</p><p>The incidence of AKI in patients treated with <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> has ranged from 6 to 11 percent in various studies [<a href="#rid19">19-21</a>]. The existence of comorbid conditions (eg, heart failure, diabetes, preexisting kidney disease) appear to increase the risk. The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study of 95 patients treated with <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> for increased intracranial pressure caused by a variety of insults, including trauma, found that 11 patients (11.6 percent) developed AKI (defined as a 0.5 mg/dL [44.2 micromol/L] or greater increase in serum creatinine or a 1 mg/dL [88.4 micromol/L] or greater increase if the baseline creatinine was &gt;2 mg/dL [177 micromol/L]) [<a href="#rid19">19</a>]. Patients who did and did not develop AKI received similar total mannitol doses (7.9±9.3 versus 10.2±10.7 g/kg) as well as maximum single mannitol doses (3.4±1.9 versus 3.1±2 g/kg). Similarly, there were no differences in the peak osmolality or the osmotic gap before the onset of kidney function impairment. The presence of heart failure and a high APACHE II score were the only factors independently associated with a higher likelihood of mannitol-induced AKI. Kidney function spontaneously returned to baseline in all patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A larger retrospective study of 432 mannitol-treated patients who were critically ill following a stroke found that the incidence of AKI (defined as a 0.3 mg/dL [26.5 micromol/L] or 50 percent increase in serum creatinine) was only 6.5 percent (with none requiring kidney replacement therapy) [<a href="#rid20">20</a>]. Diabetes, lower baseline estimated glomerular filtration rate, higher initial National Institutes of Health Stroke Scale (NIHSS) score, and concurrent use of diuretics increased the risk of mannitol-related AKI. Risk of AKI was greater among those treated with higher <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> doses, but this was not statistically significant. The lower incidence of AKI in this study compared with the study mentioned previously may be due to the lower cumulative doses of mannitol that were used or to the fact that none had traumatic brain injury.</p><p></p><p>Although tubular vacuolization also may contribute, renal vasoconstriction appears to be of primary importance in this setting, an effect which may be potentiated by the concomitant administration of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid15">15</a>]. Coadministration of <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> may also increase the risk of kidney injury [<a href="#rid18">18</a>].</p><p>AKI can be minimized by keeping the <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> dose below 0.25 g/kg every four hours (1.5 g/kg daily) [<a href="#rid3">3</a>]. Patients who develop AKI may recover kidney function rapidly (within 24 hours) if treated with one to two hemodialysis sessions to remove the excess mannitol; by contrast, patients managed without dialysis may recover kidney function more slowly (7 to 10 days) [<a href="#rid14">14</a>]. In the presence of oliguric AKI, mannitol has a half-life of 36 hours; with hemodialysis, the half-life decreases to six hours.</p><p class="headingAnchor" id="H2252878"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> acts as an osmotic diuretic, resulting in fluid losses that can lead to both volume depletion and hypernatremia. (See <a class="local">'Volume depletion and hypernatremia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retention of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> due to underlying kidney failure or mannitol-induced acute kidney injury (AKI) results in hyperosmolality and osmotic movement of water and potassium out of the cells, which can cause volume expansion, hyponatremia and metabolic acidosis (by dilution), and hyperkalemia. (See <a class="local">'Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The concentration of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> in the plasma can be estimated from the plasma osmolal gap, the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality (which does not). (See <a class="local">'Plasma osmolal gap'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A plasma osmolal gap greater than 55 mosmol/kg and a <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> dose exceeding 250 mg/kg every four hours increase the risk of reversible AKI. Higher mannitol doses are, however, sometimes used in patients judged to be at risk for brain herniation. Patients who develop kidney injury appear to recover kidney function rapidly if treated with hemodialysis to remove the excess mannitol.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GIPSTEIN RM, BOYLE JD. HYPERNATREMIA COMPLICATING PROLONGED MANNITOL DIURESIS. N Engl J Med 1965; 272:1116.</a></li><li><a class="nounderline abstract_t">Aviram A, Pfau A, Czaczkes JW, Ullmann TD. Hyperosmolality with hyponatremia, caused by inappropriate administration of mannitol. Am J Med 1967; 42:648.</a></li><li><a class="nounderline abstract_t">Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69:153.</a></li><li><a class="nounderline abstract_t">Oster JR, Singer I. Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Arch Intern Med 1999; 159:333.</a></li><li><a class="nounderline abstract_t">Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.</a></li><li><a class="nounderline abstract_t">Fanous AA, Tick RC, Gu EY, Fenstermaker RA. Life-Threatening Mannitol-Induced Hyperkalemia in Neurosurgical Patients. World Neurosurg 2016; 91:672.e5.</a></li><li><a class="nounderline abstract_t">Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.</a></li><li><a class="nounderline abstract_t">Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.</a></li><li><a class="nounderline abstract_t">Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.</a></li><li><a class="nounderline abstract_t">Seo W, Oh H. Alterations in serum osmolality, sodium, and potassium levels after repeated mannitol administration. J Neurosci Nurs 2010; 42:201.</a></li><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.607.</li><li><a class="nounderline abstract_t">DiNubile MJ. Serum osmolality (letter). N Engl J Med 1984; 310:1609.</a></li><li><a class="nounderline abstract_t">García-Morales EJ, Cariappa R, Parvin CA, et al. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med 2004; 32:986.</a></li><li><a class="nounderline abstract_t">Gadallah MF, Lynn M, Work J. Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms. Am J Med Sci 1995; 309:219.</a></li><li><a class="nounderline abstract_t">Visweswaran P, Massin EK, Dubose TD Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8:1028.</a></li><li><a class="nounderline abstract_t">Pérez-Pérez AJ, Pazos B, Sobrado J, et al. Acute renal failure following massive mannitol infusion. Am J Nephrol 2002; 22:573.</a></li><li><a class="nounderline abstract_t">Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52:886.</a></li><li><a class="nounderline abstract_t">Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491.</a></li><li><a class="nounderline abstract_t">Gondim Fde A, Aiyagari V, Shackleford A, Diringer MN. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg 2005; 103:444.</a></li><li><a class="nounderline abstract_t">Lin SY, Tang SC, Tsai LK, et al. Incidence and Risk Factors for Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective Cohort Study. Medicine (Baltimore) 2015; 94:e2032.</a></li><li><a class="nounderline abstract_t">Kim MY, Park JH, Kang NR, et al. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. J Neurosurg 2014; 120:1340.</a></li></ol></div><div id="topicVersionRevision">Topic 2333 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14281557" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : HYPERNATREMIA COMPLICATING PROLONGED MANNITOL DIURESIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6023010" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hyperosmolality with hyponatremia, caused by inappropriate administration of mannitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2111870" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mannitol-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030305" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hyponatremia, hyposmolality, and hypotonicity: tables and fables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3117392" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086258" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Life-Threatening Mannitol-Induced Hyperkalemia in Neurosurgical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402122" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447584" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glucose-induced hyperkalemia in diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/76227" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Glucose-induced hyperkalaemia: A hazard for diabetics?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804114" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Alterations in serum osmolality, sodium, and potassium levels after repeated mannitol administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804114" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alterations in serum osmolality, sodium, and potassium levels after repeated mannitol administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serum osmolality (letter)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071390" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7900744" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189872" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mannitol-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381962" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute renal failure following massive mannitol infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328926" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mannitol therapy revisited (1940-1997).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295066" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235675" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Osmolality not predictive of mannitol-induced acute renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632702" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence and Risk Factors for Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24484224" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
